Tempus AI Reports 83% Revenue Growth, Nears Adjusted EBITDA Breakeven in 2025; Details Major Acquisitions and Strategic Partnerships
Summary
Tempus AI reported an 83% revenue increase and significantly narrowed losses in 2025, fueled by strategic acquisitions, major collaborations, and substantial capital raises, despite ongoing legal challenges.
Key Events
-
Strong Financial Performance
Total net revenue surged 83% to $1.27 billion in 2025 from $693.4 million in 2024. Net loss significantly decreased to $(245.0) million from $(705.8) million, and Adjusted EBITDA improved to $(7.4) million from $(104.7) million, indicating strong operational leverage and a path towards profitability.
-
Strategic Acquisitions Expand Platform
In 2025, Tempus AI completed several key acquisitions: Ambry Genetics Corporation (hereditary cancer screening) for $375.0 million cash and 4.84 million Class A shares, Paige.AI, Inc. (digital pathology AI) for $3.0 million cash and 1.26 million Class A shares, and Deep 6 AI, Inc. (AI-powered clinical trial matching) for $4.3 million cash and $13.1 million in Class A stock. These acquisitions significantly broaden the company's product offerings and data assets.
-
Major Collaborations and Capital Raises
The company entered into a strategic collaboration with AstraZeneca and Pathos for oncology AI model development, involving a $200 million data license fee to Tempus. Existing collaborations with AstraZeneca (minimum $220M commitment) and GlaxoSmithKline (minimum $180M commitment) were highlighted. Tempus also raised $750.0 million through convertible senior notes and $195.5 million (net) from an at-the-market equity offering, with $300.0 million remaining available.
-
Ongoing Legal and Regulatory Challenges
Tempus AI is involved in patent infringement litigation with Guardant Health concerning liquid biopsy technology, with both companies filing counterclaims. The company also received a Civil Investigative Demand from the U.S. Attorney's Office regarding compliance with healthcare fraud and abuse laws, and faces class action lawsuits under the Illinois Genetic Information Privacy Act.
Analysis
Tempus AI's annual report for fiscal year 2025 reveals a period of aggressive strategic expansion and significant financial improvement. The company achieved substantial revenue growth, driven by its Diagnostics and Data & Applications segments, and dramatically reduced its net and adjusted EBITDA losses, signaling a strong trajectory towards profitability. Key strategic moves include multiple acquisitions that expand its footprint in hereditary testing, digital pathology, and AI-powered clinical trial matching. Furthermore, Tempus AI secured major multi-year collaborations with pharmaceutical giants like AstraZeneca and GlaxoSmithKline, validating its AI-driven platform and providing significant future revenue streams. The company also bolstered its liquidity through a $750 million convertible notes offering and an at-the-market equity program. While facing ongoing patent litigation and a government investigation, the overall picture is one of robust growth and strategic execution in the rapidly evolving precision medicine and AI healthcare sectors.
At the time of this filing, TEM was trading at $55.01 on NASDAQ in the Technology sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $36.22 to $104.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.